RemeGen Co

RemeGen Co Equity Growth

The Year-over-Year Equity Growth of RemeGen Co (688331.SS) as of Oct 16, 2026 is 16.81 %. In the previous year, Year-over-Year Equity Growth was -42.22 % — a change of -139.82% (higher).

Equity Growth

16.81 %

YoY

-139.82%

Last updated:

Year-over-Year Equity Growth of RemeGen Co is 2025 16.81 % . Year-over-Year Equity Growth of RemeGen Co was 2024 -42.22 % . It decreases by -139.82% higher compared to the previous year.

The RemeGen Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2019
53.44 CNY
Jan 1, 2020
1,649.61 CNY
Jan 1, 2021
-4.12 CNY
Jan 1, 2022
44.51 CNY
Jan 1, 2023
-30.98 CNY
Jan 1, 2024
-42.22 CNY
Jan 1, 2025
16.81 CNY
The RemeGen Co Equity Growth history
YEAREquity GrowthYoY
16.81 %-139.82%
-42.22 %+36.26%
-30.98 %-169.61%
44.51 %-1,179.52%
-4.12 %-100.25%
1,649.61 %+2,987.05%
53.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd, listed on the Shanghai Stock Exchange under ticker 688331.SS, is a biotechnology company headquartered in Yantai, China. The company went public on November 9, 2020, and currently employs 3,332 full-time staff. RemeGen focuses on the research, development, and manufacturing of innovative biopharmaceuticals, with a particular emphasis on therapeutic antibody drugs. Its product portfolio includes antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. The company's main products are tetacept (RC18), veldicitumab (RC48), and dual-target fusion protein (RC28), which are designed to treat conditions such as autoimmune diseases, oncology, and ophthalmology. RemeGen primarily operates within the domestic Chinese market, targeting major disease areas with its biopharmaceutical solutions. The company's website is www.remegen.cn, providing further information on its operations and products. RemeGen's business model centers on the discovery, development, and commercialization of advanced therapeutic antibodies, aiming to address significant unmet medical needs in the healthcare sector. With a strong focus on innovation, the company is positioned to contribute to the growing biotechnology landscape in China. Its operations reflect a commitment to developing cutting-edge treatments for complex health conditions, leveraging its expertise in antibody-based therapies. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Year-over-Year Equity Growth of RemeGen Co is 16.81 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — RemeGen Co

All Key Metrics — RemeGen Co